Exact Sciences Corp. (NASDAQ: EXAS)
Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott’s proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS). Julie & Holleman has already identified conflicts and believes the $105 per share deal price may be too low.
For a free, no-risk consultation or more information, please, please fill out the form below, or contact partner Scott Holleman at (917) 325-3798 or scott@julieholleman.com. There is no cost or obligation to you.
Additional Information:
The deal was announced in November and is expected to close in the second quarter of 2026.
On December 29, 2025, Exact Sciences filed a preliminary proxy statement with the SEC in connection with the upcoming shareholder vote on the merger. The proxy statement reveals a process where no other bidders were considered. Moreover, one of the company’s financial advisors indicated that Exact Sciences could be worth as much as $136.25 per share.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars in prior cases, is investigating potential claims based on the apparent unfairness of the deal, as well as potential conflicts of interest.